Presented at ESMO: the POTOMAC study on immunotherapy in non-muscle-invasive bladder cancer
About this episode
Neal Shore discusses the phase 3 POTOMAC trial of durvalumab plus BCG for bladder cancer with Ben Abbott.
Neal Shore joins Ben Abbott of The Lancet to discuss the phase 3 POTOMAC trial of durvalumab plus BCG in BCG-naïve, high-risk non-muscle-invasive bladder cancer, which is being presented at ESMO 2025. Click here to read the full article Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv
People in this episode
Host: Ben Abbott
Guest: Neal Shore
Topics covered
- immunotherapy
- bladder cancer
- clinical trials
- oncology
- ESMO
- healthcare
Keywords
- POTOMAC study
- immunotherapy
- bladder cancer
- durvalumab
- BCG
- ESMO 2025
- clinical trial
Mentioned in this episode
Organizations: The Lancet
Products: durvalumab
Books & works: POTOMAC trial
Places: non-muscle-invasive bladder cancer
More episodes of The Lancet in conversation with
- Louise Chappell and Na’ama Carlin on Personal Cancer Stories
- Susannah Stanway on the London Global Cancer Week
- Carlos Monteiro, Camila Corvalán, and Phil Baker on Ultra-Processed Foods and Human Health
- Presented at ASH: the EPCORE FL-1 study on epcoritamab in follicular lymphoma
- Presented at ESMO: the HARMONi-6 study on a bispecific antibody therapy for squamous NSCLC
- Stephen Chan on the Lancet Commission on addressing the global hepatocellular carcinoma burden
Explore listener stats, chart rankings, contacts and more on the The Lancet in conversation with podcast page.